← Eichor
Study identifier: NCT07168213 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparison of Two SpO2 Targets With Two Different Oximeters - Impact on FiO2 During Nasal High Flow Oxygen Therapy

Condition: Oxygen Delivery · Acute Respiratory Failure · High Flow Oxygen Therapy  ·  Sponsor: Laval University

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Francois Lellouche Principal Investigator  ·  418-656-8711  ·  francois.lellouche@criucpq.ulaval.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Institut universitaire de cardiologie et de pneumologie de Québec - Université LavalQuébec, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07168213